Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women

Journal of Infectious Diseases

Volumn 187, Issue 3, 2003, Pages 375-384

  Tuomala, Ruth E ^a   O'Driscoll, Peter T ^b   Bremer, James W ^e   Jennings, Cheryl ^e   Xu, Chong ^a   Read, Jennifer S ^c   Matzen, Elaine ^d   Landay, Alan ^e   Zorrilla, Carmen ^f   Blattner, William ^b   Charurat, Manhattan ^b   Anderson, Deborah J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CESAREAN SECTION; CONTROLLED STUDY; FEMALE; GENITAL SYSTEM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; STATISTICAL ANALYSIS; UTERINE CERVIX CYTOLOGY; VERTICAL TRANSMISSION; VIRUS SHEDDING; VIRUS TITRATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CERVIX UTERI; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; RNA, VIRAL; VAGINA; VIRUS SHEDDING;

EID: 0037314746     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367706     Document Type: Article

References (67)

1. Mofenson LM. Mother-child HIV-1 transmission. Obstet Gynecol Clin North Am 1997; 24:750-84.
2. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-93.
3. Garcia PM, Kalish LA, Pitt J, et al. RNA and transmission: maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study (WITS). N Engl J Med 1999; 341:394-402.
4. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1. French Perinatal Cohort Studies. SEROGEST Cohort Group. J Infect Dis 1997; 175:172-5.
5. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377-85.
6. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:232-6.
7. Shapiro DE, Sperling RS, Coombs RW. Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Pediatric AIDS Clinical Trials Group 076 Study Group. Lancet 1999; 354:156-8.
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-80.
9. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1999; 94:641-6.
10. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
11. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-93.
12. Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175:567-75.
13. + levels. J Acquir Immune Defic Syndr 1994; 7:718-26.
14. Turner BJ, Hauck WW, Fanning R, Markson LE. Cigarette smoking and mother-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:327-37.
15. Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996; 10:273-82.
16. Bulterys M, Landesman S, Burns DN, et al. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:76-82.
17. Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. AIDS 1996; 10:1249-56.
18. Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 1997; 176:414-20.
19. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334:1617-23.
20. Newell ML, Dunn DT, Peckham CS, et al. Vertical transmission of HIV-1: maternal immune status and obstetric factors. European Collaborative Study. AIDS 1996; 10:1675-81.
21. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994; 271:1925-30.
22. Mandelbrot L, Mayaux M, Bongain A, et al. Obstetrics: obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1. The French Perinatal Cohorts. Am J Obstet Gynecol 1996; 175: 661-7.
23. Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TD. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS 1998; 12:513-20.
24. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173:585-9.
25. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15:357-68.
26. St. Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993; 269:2853-9.
27. Ryder RW, Nsa W, Hassig SE, et al. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. N Engl J Med 1989; 320:1637-42.
28. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-87.
29. The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035-9.
30. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS 1998; 12:205-10.
31. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280:55-60.
32. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-12.
33. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000; 181:99-106.
34. Sheon AR, Fox HE, Rich KC, et al. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: design, methods, and baseline data. J Womens Health 1996; 5:69-78.
35. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition of AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17):1-19.
36. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guidelines for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993; 14:702-15.
37. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 1992; 30:1787-94.
38. Xu C, Politch JA, Tucker L, Mayer KH, Seage GR, Anderson DJ. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis 1997; 176:941-7.
39. Kwok S, Erlich G, Poiesz B, Kalish R, Sninsky JJ. Enzymatic amplification of HTLV-I viral sequences from peripheral blood mononuclear cells and infected tissues. Blood 1988; 72:1117-23.
40. Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific olgonucleotide probes. Nature 1986; 324:163-6.
41. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14: 415-21.
42. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-82.
43. Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1996; 175:122-9.
44. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999; 2:154-66.
45. Iversen AK, Larsen AR, Jenson T, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177:1214-20.
46. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-7.
47. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya. JAMA 1993; 269:2860-4.
48. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997; 175:57-62.
49. Loussert-Ajaka I, Mandelbrot L, Delmas MC, et al. HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS 1997; 11:1575-81.
50. Cu-Uvin SC, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol 1997; 90:739-43.
51. Gouston C, McFarland W, Katzenstein D. Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Infect Dis 1998; 177:1100-3.
52. Baron P, Bremer J, Wasserman SS, et al. Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. Division of AIDS Treatment Research Initiative 009 Study Group. J Clin Microbiol 2000; 38:3822-4.
53. Seck K, Samb N, Tempesta S, et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Transm Infect 2001; 77:190-3.
54. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000; 14:F69-75.
55. Seo K, McGregor JA, French JL. Preterm birth is associated with increased risk of maternal and neonatal infection. Obstet Gynecol 1992; 79:75-80.
56. Mueller-Heuback E, Rubinstein DN, Schwarz SS. Histologic chorioamnionitis and preterm delivery in different patient populations. Obstet Gynecol 1990; 75:622-6.
57. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Echenbach DA. A case-control study of chorioamniotic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972-8.
58. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347:1647-50.
59. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-22.
60. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HW-1. AIDS 2001; 15:105-10.
61. Poss M, Martin HL, Kreiss JK, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 1995;69: 8118-22.
62. Wainberg MA, Beaulieu R, Tsoukas C, Thomas R. Detection of zidovudine-resistant variants of HIV-1 in genital fluids. AIDS 1993;7: 433-4.
63. Di Stefano M, Fiore JR, Monno L, Lepera A, Pastore G, Angarano G. Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women largely treated with antiretroviral agents. AIDS 1999; 13:992-4.
64. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses 1996; 12: 107-15.
65. Ellerbrock TV, Lennox JL, Clancy KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001; 184:28-36.
66. Panther LA, Tucker L, Xu C, Tuomala RE, Mullins JI, Anderson DJ. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J Infect Dis 2000; 181:555-63.
67. Merigan TC. Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. J Reprod Immunol 1998; 41:177-85.